Clinical trial · Interventional
CEV With/Without Periocular Carboplatin Chemotherapy for Extraocular Retinoblastoma
CEV With/Without Periocular Carboplatin Chemotherapy for Nonmetastatic Extraocular Retinoblastoma Carboplatin--A Single Center, Retrospective Study to Evaluate the Efficacy of Carboplatin in Subjects With Retinoblastoma
NCT02319486CI-TRIAL-00017319completedPhase 4Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will evaluate a uniform chemotherapy protocol for nonmetastatic extraocular retinoblastoma
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Retinoblastoma | Retinoblastoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| carboplatin periocular injection | Drug | — | UNRESOLVED |
| CEV chemotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- CEV with/without carboplatin
- description
- CEV chemotherapy(CEV Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months) together with/without 20mg/2ml carboplatin periocular injection
- interventionNames
- Drug: carboplatin periocular injection
- Drug: CEV chemotherapy
Primary outcomes (1)
- measure
- Event Free Survival Rate
- timeFrame
- 18 months
- description
- measure the event free survival rate for the patients at 18 months: patients that without tumor relapse or metastasis
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * IRSS stage II or stage IIIa RB patients. * for patients with IRSS stage II disease, if scleral surface invasion alone was observed, only systemic chemotherapy was administered, whereas other IRSS stage II and IIIa patients received systemic chemotherapy plus additional local chemotherapy. * no tumor-related treatment was given prior to this chemotherapy regimen. Exclusion Criteria: * metastasis, including lymph node metastasis. * the diagnosis of IRSS stage I or above in the non-target eye.
References
Publications (0)
Data not yet available
No reference posted for this study.